BioCorRx Pharmaceuticals Inc., a clinical-stage subsidiary of BioCorRx Inc. (OTCQB: BICX), is dedicated to developing innovative treatments for substance use disorders, including opioid and alcohol addiction, as part of the parent company's broader mission to break the cycle of addiction through holistic recovery programs. In a landmark acquisition completed in March 2025 from USWM LLC, BioCorRx Pharmaceuticals secured Lucemyra (lofexidine), marking its first FDA-approved commercialized product and a key revenue driver in the fight against the opioid crisis. As the only non-opioid medication approved by the FDA to mitigate opioid withdrawal symptoms in adults, Lucemyra provides essential relief from issues like anxiety, insomnia, and physical discomfort during the critical first days of detoxification, helping patients transition more comfortably to long-term recovery without relying on opioids. Common side effects include dizziness, dry mouth, and low blood pressure, and it is supported by resources like the LUminate Support Program to ensure safe and effective use.